Abstract
Glioblastoma is a common primary brain tumor with aggressive malignancy, resulting in poor outcomes and high mortality. Vitexin, a natural flavonoid, has been reported to inhibit growth in various cancers. This study investigated the effects of vitexin on human glioblastoma cells (LN-18). Results demonstrated that vitexin inhibited cell viability in a dose‑ and time‑dependent manner and induced G2/M cell cycle arrest. Furthermore, vitexin induced cell apoptosis and inhibited the Akt/mTOR signaling pathway. These findings suggest vitexin may be a potential therapeutic agent for malignant glioblastoma.
Introduction
Glioblastoma (GBM) is the most aggressive form of brain cancer, with a median survival time of only 12–15 months. Its rapid proliferation and recurrence make it exceptionally difficult to treat. While Vitexin has shown anti-cancer properties in liver and esophageal cancers, its impact on GBM was previously unknown. This study sought to determine if Vitexin could effectively target GBM cells and identify the molecular pathways involved.
Methods
The researchers utilized the LN-18 human glioblastoma cell line and employed several molecular biology techniques:
- Cell Viability (CCK-8 Assay): To measure survival across different doses (10–160 µM) and time intervals (24h and 48h).
- Flow Cytometry: Used with Propidium Iodide (PI) staining to analyze cell cycle distribution and Annexin V-FITC/PI to quantify apoptosis.
- Western Blotting: To measure the expression of cleaved-PARP (an apoptosis marker) and the activation (phosphorylation) levels of Akt and mTOR.
Results
Inhibition of Cell Growth
Vitexin significantly reduced the viability of LN-18 cells in both a dose- and time-dependent manner. The concentration required to inhibit 50% of cell growth (IC50) was determined to be 32.32 µM at 24 hours and 25.32 µM at 48 hours.
G2/M Phase Arrest
Treatment with Vitexin caused a massive shift in the cell population by targeting the G2/M checkpoint—the phase where cells prepare for division. At a dose of 80 µM, the percentage of cells arrested in the G2/M phase jumped from approximately 14% to over 52%, effectively "freezing" the tumor's expansion.
Apoptosis and Pathway Suppression
Vitexin triggered programmed cell death, as evidenced by increased levels of cleaved-PARP and visual signs of nuclear fragmentation. This effect is driven by the suppression of the Akt/mTOR signaling pathway, a master switch for cell survival that is often overactive in GBM. Western blots confirmed that Vitexin effectively flips this switch to "OFF" by decreasing the levels of phosphorylated Akt and mTOR.
Conclusion and Future Directions
Vitexin represents a promising natural lead for glioblastoma treatment, hitting a critical vulnerability in cancer cell signaling. However, significant hurdles remain, including determining if Vitexin can cross the blood-brain barrier and validating these results in in vivo animal models to ensure safety and efficacy in a complex biological system.
Summary updated